Ms. Gash is a Director in Eli Lilly’s global safety organization focusing specifically in the area of Benefit-Risk Management. In this role she oversees Consultants who are responsible for implementation of global processes related to risk minimization planning (RMiP), and specialized pharmacoepidemiology (PE) studies in partnership with scientific experts. She additionally oversees a group of Benefit-Risk Scientists who are responsible for the development and integration of benefit-risk assessments across the product lifecycle. Her role includes influencing complex business or technical issues in the management of project resources, driving solutions leading to consistency in tracking, documenting and communicating project metrics, anticipating and resolving key technical and operational problems, and adapting plans and implementing appropriate changes in response to rapidly changing requirements and environment. Debbie received her B.A. in Psychology from the University of Indianapolis and a Master of Science in Counseling Psychology from Indiana University in Indianapolis. She has been with Eli Lilly and Company for 15 years. Her other experiences at Lilly include oversight and monitoring of early and late phase clinical trials and medical planning for compounds marketed in the US. Debbie has also held positions in Human Resources and Issues Management at Lilly.